Lubrication of Direct-Compressible Blends with Magnesium Stearate Monohydrate and Dihydrate - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Lubrication of Direct-Compressible Blends with Magnesium Stearate Monohydrate and Dihydrate
The influence of magnesium stearate (MgSt) on powder lubrication and finished solid-dose properties presents big challenges to drug manufacturers.


Pharmaceutical Technology


Results and discussion


Figure 2
Solid-state characterization of MgSt hydrates. Isolation of the dihydrate and monohydrate forms by using the vegetable source of MgSt was successfully conducted by the Mallinckrodt team (10). The results of the solid-state characterization showed that on the basis of particle and molecular characterization, substantive evidence exists to support differences in the nature and behavior of the two hydrates (11). Lubrication efficacy of MgSt, vegetable or animal source, has been widely associated with its physicochemical properties such as crystalline state, crystal shape, particle size, particle-size distribution, and particle morphology with a given fatty acid composition consisting of stearic and palmitic acids and fatty acid ratio (9).


Table III: MgSt pseudopolymorph particle size and percent water.
Powder X-ray diffraction. Figure 1 shows the results of the powder X-ray diffraction conducted on the MgSt hydrates.


Figure 3
Scanning electron microscope. Figure 2 shows the results of the characterization conducted on the MgSt hydrates using scanning electron microscopy at a magnification of 2500×.


Figure 4
Particle size, percent water, and concentration of neat MgSt-M and MgSt-D. Results of particle size and free and bound-moisture analysis for the MgSt hydrates are shown in Table III. The neat dihydrate had a concentration of 95.4%, and the neat monohydrate had a concentration of 92.0%. The results also indicate that the nominal mean particle size of the monohydrate is 10.6 μm, and the dihydrate has a nominal mean particle size of 14.3 μm. In addition, percent bound moisture was 2.8% for MgSt-M and 5.6% for MgSt-D. Although the percent of free water was generally low, MgSt-M had 0.6%, and little or no free water was found in MgSt-D.


Figure 5
Differential scanning calorimetry, thermogravimetry, and NIR spectroscopy. The profiles depicted in Figures 3a–c show the results of the DSC, thermogravimetry, and NIR reflectance for the MgSt hydrates. These profiles depict the differences between the hydrates of MgSt. The NIR spectra were provided by Kaufman (11).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
21%
To all process for new products only
13%
To select process for new products only
26%
To select processes for both new and legacy products
21%
Do not use QbD
21%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here